ITGA4 (VLA-4) and NG2 — the niche-adhesion axis of KMT2A-rearranged B-ALL, and the one approved drug that hits it
also called NG2-ITGA4 axis · VLA-4 / alpha-4 integrin adhesion · natalizumab repurposing in KMT2A-r B-ALL · CSPG4-ITGA4
Leukaemia cells stick to the bone marrow using a surface hook called integrin alpha-4, and in this genetic type of leukaemia that hook works together with a second molecule, NG2, that the fusion protein itself switches on. An antibody already licensed for multiple sclerosis blocks the hook, and in mice carrying children's leukaemia it slowed the disease and made standard chemotherapy work better.
The same thing, for a scientist
NG2 (CSPG4) is a direct transcriptional target of KMT2A fusions and a long-standing immunophenotypic hallmark of KMT2A-rearranged B-ALL, associated with poor prognosis, early relapse and glucocorticoid resistance [E1]. Its mechanism at the niche interface is now defined: **NG2 and the alpha-4 integrin subunit ITGA4 form a biological axis** in which NG2 expression promotes proliferation and migration of KMT2A-r B-ALL cells and is associated with **Rho GTPase activity in an ITGA4-dependent manner**; combined genetic ablation of both genes significantly delayed disease onset and prolonged survival in immunodeficient mice; and **natalizumab, an FDA/EMA-approved monoclonal antibody against ITGA4, delayed leukaemia progression and potentiated standard-of-care chemotherapy in KMT2A-rearranged B-ALL patient-derived xenografts** [E2]. ITGA4 is the alpha chain of VLA-4, the integrin that binds VCAM-1 on marrow stroma and fibronectin in marrow matrix, and VLA-4/VCAM-1 is the canonical adhesion arm of the niche alongside the CXCL12-CXCR4 chemokine arm. This is the strongest actionable niche-directed result in this beat: it is in **KMT2A-rearranged B-ALL** rather than a murine myeloid model, and the drug is already approved with paediatric exposure.
Why this is the most useful entry in the beat
Almost every other niche mechanism written here has one or more of three defects: it is murine, it is myeloid (MLL-AF9), or its pharmacology does not exist. 2 has none of them.
- Right disease. KMT2A-rearranged B-ALL, in patient-derived xenografts.
- Right molecule. ITGA4 is the alpha chain of VLA-4, the integrin that binds VCAM-1 on marrow stromal cells and fibronectin in matrix. Adhesion-mediated drug resistance through VLA-4 is a decades-old idea in myeloma and AML; this is its specific instantiation in this genotype.
- Right drug. Natalizumab is approved by FDA and EMA for multiple sclerosis and Crohn's disease, with an established dosing and safety record including in adolescents. Repurposing is a regulatory and toxicology problem, not a discovery problem.
- Right readout. It delayed progression and potentiated standard-of-care chemotherapy — the combination effect that a niche-disruption strategy is supposed to produce and that plerixafor did not deliver in POE 10-03 (
trial-poe-10-03-plerixafor-paediatric).
The partner molecule closes a loop this graph already had open. NG2 positivity is one of the diagnostic hallmarks of KMT2A-rearranged B-ALL (concept-flow-cytometry-immunophenotype-kmt2a-r), it drives CNS infiltration (concept-cns-involvement-at-diagnosis), and it causes glucocorticoid resistance by downregulating NR3C1 through FLT3/AP-1 1. Now the same molecule turns out to work through an integrin — so the fusion's own target gene is a niche-adhesion effector. Niche dependency in this disease is not only something the environment imposes on the cell; part of it is transcribed by the fusion.
The NG2 naming hazard, stated so nobody trips on it
NG2/CSPG4 appears in this beat in two completely different roles and they must not be confused.
- Niche cell marker. NG2 marks the rare periarteriolar pericytes that maintain HSC quiescence in mouse marrow (
cell-type-ng2-periarteriolar-cell). - Leukaemic blast antigen. In the KMT2A literature NG2 is overwhelmingly a blast marker: of the 19 PubMed records intersecting NG2/CSPG4/pericyte terms with the KMT2A disease half, the great majority concern NG2 on leukaemic cells as a diagnostic marker, a prognostic factor, a CNS-infiltration effector, a glucocorticoid-resistance mechanism or a CAR-T target, and only one is about NG2+ niche pericytes.
The hazard is practical, not semantic. An NG2-directed agent — and CSPG4-specific CAR T cells for high-risk childhood BCP-ALL have been described — would engage both the blast and the periarteriolar niche cell. Whether that is a liability (destroying the HSC-quiescence niche the patient needs) or an unexpected advantage (removing a niche compartment along with the blast) is unknown and has not been asked. Targeting ITGA4 with natalizumab does not have this problem, because ITGA4 is not the pericyte marker.
| mechanism class | integrin-mediated niche adhesion |
|---|---|
| axis | NG2 (CSPG4) with ITGA4 (alpha-4 integrin, the alpha chain of VLA-4) signalling to Rho GTPases |
| ng2 dual role warning | NG2/CSPG4 marks BOTH the periarteriolar niche pericyte that maintains HSC quiescence and the KMT2A-rearranged leukaemic blast; of 19 PubMed records intersecting NG2/CSPG4/pericyte terms with the KMT2A disease half, nearly all concern the blast and one concerns the niche pericyte. An NG2-directed agent would engage both; an ITGA4-directed agent would not. |
| literature size | the VLA-4/VCAM-1/integrin-alpha4 x KMT2A PubMed intersection was 2 records on the terms first used; broadening to NG2/CSPG4/pericyte terms returns 19, nearly all about the blast |
canonical niche ligands of vla4
[ "VCAM-1 on marrow stromal and endothelial cells", "fibronectin in marrow extracellular matrix" ]
drug
{
"name": "natalizumab",
"target": "ITGA4",
"modality": "humanised monoclonal antibody",
"regulatory_status": "FDA and EMA approved (multiple sclerosis, Crohn's disease)",
"preclinical_result_in_kmt2a": "delayed leukaemia progression and potentiated standard-of-care chemotherapy in KMT2A-rearranged B-ALL patient-derived xenografts",
"known_class_risk": "progressive multifocal leukoencephalopathy (PML) associated with prolonged natalizumab exposure in multiple sclerosis, risk stratified by JC virus serostatus"
}ng2 other roles in this disease
[ "diagnostic immunophenotypic hallmark of KMT2A-rearranged B-ALL", "CNS infiltration and invasiveness", "glucocorticoid resistance via FLT3/AP-1 downregulation of NR3C1", "CSPG4-specific CAR T cell target in high-risk childhood BCP-ALL" ]
related entries
[ "concept-flow-cytometry-immunophenotype-kmt2a-r", "concept-cns-involvement-at-diagnosis", "collab-menendez-bueno-barcelona", "cell-type-ng2-periarteriolar-cell" ]
atlas refs
[
{
"label": "NG2-ITGA4 axis and natalizumab in KMT2A-r B-ALL PDX",
"pmid": "42345361",
"title": "NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.",
"authors": "Rubio-Gayarre A, Vinyoles M, Tejedor JR, et al.",
"venue": "Blood",
"year": 2026,
"title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
},
{
"label": "NG2 as a direct MLL-AF4 target driving glucocorticoid resistance",
"pmid": "39093982",
"title": "NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression.",
"authors": "Lopez-Millan B, Rubio-Gayarre A, Vinyoles M, et al.",
"venue": "Blood",
"year": 2024,
"title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
}
]- Natalizumab's known association with progressive multifocal leukoencephalopathy arises in chronically immunosuppressed patients; a child in leukaemia induction is profoundly immunosuppressed, which is the worst possible background for that specific risk.
- VLA-4 blockade mobilises normal haematopoietic progenitors as well as blasts, so like CXCR4 antagonism it strips the patient's own marrow of its anchor during the period it most needs to regenerate.
- Blocking adhesion releases blasts into the circulation in a disease that presents with hyperleukocytosis; the mobilisation hazard that applies to plerixafor applies here.
- E1 and E2 come from the same group, so the axis has no independent replication; a therapy argument built on one laboratory's pair of papers is exactly the profile this project has been burned by.
- NG2 also drives CNS infiltration. If ITGA4 blockade impedes marrow adhesion without impeding CNS tropism, it could shift disease towards the sanctuary site that already carries the worst prognosis in this population.
- Does natalizumab work in INFANT KMT2A::AFF1 B-ALL specifically, and at what exposure? The PDX result does not report an infant-specific arm and natalizumab has no infant pharmacokinetic data.
- Natalizumab carries a class risk of progressive multifocal leukoencephalopathy on prolonged exposure. Is a short, induction-length course in a leukaemia protocol below the exposure threshold that risk depends on?
- PDX models use murine stroma. Does the natalizumab effect depend on human VCAM-1, and would it be larger in a humanised-niche model?
- Would blocking ITGA4 and CXCR4 together be additive? They are the two arms of the same niche interaction and no study has combined them in this genotype.
- NG2 causes glucocorticoid resistance and NG2 signals through ITGA4. Does natalizumab restore glucocorticoid sensitivity, which would be the cheapest possible combination in infant ALL because steroids are already in the backbone?
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
NG2 is an epigenetically regulated direct target gene of the MLL-AF4 fusion protein and its expression is a hallmark of MLL-rearranged B-ALL while being minimally expressed in healthy haematopoietic cells; NG2 negatively regulates expression of the glucocorticoid receptor NR3C1 and confers glucocorticoid resistance to MLLr B-ALL cells, mechanistically by interacting with FLT3 to produce ligand-independent activation of FLT3 signalling and downregulation of NR3C1 via AP-1-mediated transrepression.
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression · Lopez-Millan B, Rubio-Gayarre A, Vinyoles M, Trincado JL, Fraga MF, Fernandez-Fuentes N, Guerrero-Murillo M, Martinez A, et al. · Blood 2024What this evidence cannot show
Single-group finding from the Barcelona group (`collab-menendez-bueno-barcelona`), not independently replicated as far as this beat found. NG2 positivity as an MLLr hallmark is long established; the causal chain NG2 to FLT3 to AP-1 to NR3C1 is the new and less-tested part. Cell lines and primary cells; the abstract does not report a clinical correlation of NG2 with prednisone response in a trial cohort. Read: abstract only.
Evidence that argues against this (1)
- NG2's role in this disease is not confined to, and may not be primarily, glucocorticoid resistance: the same molecule was earlier shown to drive leukaemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL, with NG2 markedly upregulated on CNS-infiltrating blasts and NG2 blockade almost abolishing CNS engraftment. A single molecule carrying prognosis, CNS tropism, integrin signalling and steroid resistance is doing a great deal of explanatory work, and the relative contribution of each is not established. Read: abstract only. Prieto C et al. 2018
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In KMT2A-rearranged B-ALL, the alpha-4 integrin subunit ITGA4 and NG2 form a key biological axis contributing to leukaemic aggressiveness: NG2 expression promotes proliferation and migration of KMT2A-r B-ALL cells and is associated with Rho GTPase activity in an ITGA4-dependent manner; combined genetic ablation of ITGA4 and NG2 in immunodeficient mice significantly delayed disease onset and prolonged survival; and natalizumab, an FDA- and EMA-approved monoclonal antibody targeting ITGA4, delayed leukaemia progression and potentiated the efficacy of standard-of-care chemotherapy in KMT2A-rearranged B-ALL patient-derived xenograft models.
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab · Rubio-Gayarre A, Vinyoles M, Tejedor JR, Guerrero-Murillo M, Fernandez-Fuentes N, Caracuel-Peramos R, Plaza-Calonge MC, Martinez-Moreno A, et al. · Blood 2026What this evidence cannot show
2026 publication from the same group as E1, so E1 and E2 are not independent. Patient-derived xenografts in immunodeficient mice, which lack the immune compartment and carry a murine rather than human stroma - a material limitation for an adhesion mechanism that depends on stromal VCAM-1. 'Delayed progression' and 'potentiated chemotherapy' are survival-curve statements whose effect sizes are not given in the abstract. No infant-specific arm is described, and the number of PDX models is not stated. Natalizumab's mechanism here is assumed to be adhesion blockade; the abstract does not report a VCAM-1-binding readout. Read: abstract only.
Evidence that argues against this (1)
- The clinical precedent for niche-adhesion disruption in paediatric leukaemia is discouraging in a way this result has to answer. The CXCR4 antagonist plerixafor, targeting the chemokine arm of the same niche interaction, engaged its target in children with relapsed leukaemia - mobilizing blasts a median 3.4-fold, correlating with surface CXCR4 - and produced only three responses in eighteen evaluable patients, none in ALL. Target engagement in this compartment has already been shown not to guarantee benefit, and the integrin arm has not yet been tested clinically in leukaemia at all. Read: abstract only. Cooper TM et al. 2017
- E3moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
A proteomic study of fetal- and adult-derived MLL-rearranged leukaemia, integrating the pre-leukaemic cell proteome with its secretome and the proteomic composition of the extracellular environment of normal progenitors, reports differential regulation of Igf2 bioavailability and of the VLA-4 dimer and its ligandome upon initiation of fetal- and adult-origin leukaemia, with implications for human MLL-rearranged leukaemia cells' ability to communicate with their environment through granule proteins.
A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia · Jassinskaja M, Ghosh S, Watral J, Davoudi M, Claesson Stern M, Daher U, Eldeeb M, Zhang Q, et al. · Leukemia 2024What this evidence cannot show
Mouse MLL::ENL, proteomic and descriptive; VLA-4 regulation is one finding among several and no functional adhesion or drug experiment on VLA-4 is reported in the abstract. Cited here as independent, differently derived evidence that the VLA-4 interface is differentially regulated as MLL-rearranged leukaemia initiates, not as evidence for the therapeutic claim. Read: abstract only.
Evidence that argues against this (1)
- The same study's central finding cuts against a simple environment-determines-behaviour reading: fetal MLL::ENL-expressing lymphomyeloid multipotent progenitors are intrinsically programmed towards a lymphoid fate yet give rise to MYELOID leukaemia in vivo, which is the opposite direction from the heterochronic transplantation result in which a neonatal environment produced B-lymphoid character. Extracellular regulation is demonstrated; its direction and dominance are not. Read: abstract only. Rowe RG et al. 2019
the integrin adhesion arm of the niche interaction, alongside the CXCL12-CXCR4 chemokine arm
NG2-ITGA4 axis drives proliferation, migration and leukaemic aggressiveness in KMT2A-r B-ALL
- depends on →KMT2A::AFF1 (MLL-AF4), t(4;11)(q21;q23)
NG2 is a direct epigenetically regulated target gene of the MLL-AF4 (KMT2A::AFF1) fusion
both NG2 papers are from this group; the axis has no independent replication
NG2/CSPG4 names both this leukaemic axis and the niche pericyte; an NG2-directed agent would engage both
natalizumab potentiated standard-of-care chemotherapy in KMT2A-r B-ALL PDX, the combination effect niche disruption predicts
the same NG2 molecule drives CNS infiltration; adhesion blockade in marrow may not impede CNS tropism
VLA-4 anchors normal progenitors as well as blasts
the integrin the mechanism is named after
the VCAM1 half of VLA-4/VCAM-1 adhesion